FNDC4 recombinant protein

FNDC4 Protein, Human, Recombinant (ECD, mFc Tag)

Cat. Num. AAA8121883

• Gene Names: FNDC4; FRCP1
• Purity: >85.4% as determined by SDS-PAGE
• Synonyms: FNDC4; FNDC4 Protein; Human; Recombinant (ECD; mFc Tag); Human FNDC4/FRCP1 Protein (ECD; Fc Tag); FRCP1 Protein; fibronectin type III domain containing 4; FNDC4 recombinant protein

• Host: HEK293 Cells
• Purity/Purification: >85.4% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Sequence: Met1-Thr167

• Species: Human
• Endotoxin: <1.0EU per ug protein as determined by the LAL method.
• Predicted N Terminal: Asp 45
• Tag: C-mouse IgG1-Fc
• Protein Construction: A DNA sequence encoding the human FNDC4 (NP_073734.1)(Met1-Thr167) was expressed with the Fc region of mouse IgG1 at the C-terminus.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.; In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid.; They are shipped out with blue ice.

SDS-Page

Related Product Information for FNDC4 recombinant protein

Background: FNDC4 acts as an anti-inflammatory factor on macrophages and improves mouse model of induced colitis. FNDC4 could suppress osteoclast formation via NF-kappaB pathway and downregulation of CXCL10. Analysis of binding of FNDC4 to different immune cell types reveals strong and specific binding to macrophages and monocytes. FNDC4 treatment of bone marrow-derived macrophages in vitro results in reduced phagocytosis, increased cell survival and reduced proinflammatory chemokine expression. Hence, treatment with FNDC4 results in a state of dampened macrophage activity, while enhancing their survival. That FNDC4 may be a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases.

NCBI and Uniprot Product Information

• NCBI GI #: 12383064
• NCBI GeneID: 64838
• NCBI Accession #: NP_073734.1
• NCBI GenBank Nucleotide #: NM_022823.2
• UniProt Accession #: Q9H6D8; D6W560
• Molecular Weight: ~16.0 kDa. (Extracellular domain, human (aa 45-167) / mouse (aa 41-163)) is untagged. FNDC4 extracellular domain has 100% identity between human, mouse, rat, dog and monkey.
• NCBI Official Full Name: fibronectin type III domain-containing protein 4
• NCBI Official Synonym Full Names: fibronectin type III domain containing 4
• NCBI Official Symbol: FNDC4
• NCBI Official Synonym Symbols: FRCP1
• NCBI Protein Information: fibronectin type III domain-containing protein 4
• UniProt Protein Name: Fibronectin type III domain-containing protein 4
• Protein Family: Fibronectin type III domain-containing protein
• UniProt Gene Name: FNDC4
• UniProt Synonym Gene Names: FRCP1
• UniProt Entry Name: FNDC4_HUMAN

Uniprot Description

FNDC4:

Protein type: Membrane protein, integral

Chromosomal Location of Human Ortholog: 2p23.3

Cellular Component: endoplasmic reticulum; integral to membrane; plasma membrane